Histone deacetylases in skeletal development and bone mass maintenance

Gene

Volumn 474, Issue 1-2, 2011, Pages 1-11

  McGee Lawrence, Meghan E ^a   Westendorf, Jennifer J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hdac; Osteoblast; Osteoclast; Valproate; Vorinostat

Indexed keywords

AR 42; BELINOSTAT; CHR 2845; CHR 3996; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HOX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JNJ 26481585; LYMPHOID ENHANCER FACTOR 1; PANOBINOSTAT; PCI 24781; RESMINOSTAT; ROMIDEPSIN; SB 939; SIRTUIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 521;

ACUTE GRANULOCYTIC LEUKEMIA; BASIC MULTICELLULAR UNIT; BONE; BONE CELL; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE MATRIX; BONE METABOLISM; BREAST CANCER; CARTILAGE; CARTILAGE CELL; CELL NUCLEUS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG MECHANISM; FALLOPIAN TUBE CANCER; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GERM LINE; GLIOBLASTOMA; GLIOMA; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HOMEOSTASIS; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSPLENISM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHADENOPATHY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT EPITHELIAL NEOPLASM; MELANOMA; MULTICELLULAR SPHEROID; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEUROECTODERM TUMOR; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERITONEUM CANCER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SARCOMA; SMALL INTESTINE CANCER; SOLID TUMOR; STOMACH CANCER; THROMBOCYTHEMIA; THYMOMA; THYMUS CANCER; THYMUS CARCINOMA; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; UTERUS CANCER;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; OSTEOBLASTS; OSTEOCLASTS; RATS; TRANSCRIPTION FACTORS;

EID: 79952003783     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2010.12.003     Document Type: Review

References (103)

1. Anon Bone Health and Osteoporosis: a Report of the Surgeon General 2004, 1-355. U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD.
2. Arnold M.A., et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev. Cell 2007, 12:377-389.
3. Backesjo C.M., Li Y., Lindgren U., Haldosen L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 2006, 21:993-1002.
4. Backesjo C.M., Li Y., Lindgren U., Haldosen L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs 2009, 189:93-97.
5. Bhaskara S., et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol. Cell 2008, 30:61-72.
6. Boluk A., Guzelipek M., Savli H., Temel I., Ozisik H.I., Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol. Res. 2004, 50:93-97.
7. Burr D.B. Targeted and nontargeted remodeling. Bone 2002, 30:2-4.
8. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 2004, 24:8467-8476.
9. Chang S., Young B.D., Li S., Qi X., Richardson J.A., Olson E.N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126:321-334.
10. Chang M.K., et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J. Immunol. 2008, 181:1232-1244.
11. Cho H.H., Park H.T., Kim Y.J., Bae Y.C., Suh K.T., Jung J.S. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J. Cell. Biochem. 2005, 96:533-542.
12. Choo M.K., Yeo H., Zayzafoon M. NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differentiation. Bone 2009, 45:579-589.
13. Choudhary C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
14. de Boer J., Licht R., Bongers M., van der Klundert T., Arends R., van Blitterswijk C. Inhibition of histone acetylation as a tool in bone tissue engineering. Tissue Eng. 2006, 12:2927-2937.
15. Di Bernardo G., et al. Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev. 2009, 18:573-581.
16. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 2005, 45:495-528.
17. Edwards J.R., et al. The aging associated gene SIRT-1 regulates osteoclast formation and bone mass in vivo. J. Bone Miner. Res. 2007, 22:S29.
18. EFFO and NOF Who are candidates for prevention and treatment for osteoporosis?. Osteoporos. Int. 1997, 7:1-6.
19. Elbaz A., Rivas D., Duque G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology 2009, 10:747-755.
20. Elliott J.O., Jacobson M.P., Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007, 16:22-34.
21. Fischle W., et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 2002, 9:45-57.
22. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
23. Gori F., Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Khosla S., Riggs B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000, 141:4768-4776.
24. Grozinger C.M., Hassig C.A., Schreiber S.L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl Acad. Sci. USA 1999, 96:4868-4873.
25. Haberland M., Mokalled M.H., Montgomery R.L., Olson E.N. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev. 2009, 23:1625-1630.
26. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10:32-42.
27. Haberland M., Carrer M., Mokalled M.H., Montgomery R.L., Olson E.N. Redundant control of adipogenesis by histone deacetylases 1 and 2. J. Biol. Chem. 2010, 285:14663-14670.
28. Hauge E.M., Qvesel D., Eriksen E.F., Mosekilde L., Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J. Bone Miner. Res. 2001, 16:1575-1582.
29. Hesse E., Saito H., Kiviranta R., Correa D., Yamana K., Neff L., Toben D., Duda G., Atfi A., Geoffroy V., Horne W.C., Baron R. Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity. J. Cell. Biol. 2010, 16:1271-1283.
30. Hutt D.M., et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 2010, 6:25-33.
31. Iwami K., Moriyama T. Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int. J. Biochem. 1993, 25:1631-1635.
32. Jensen E.D., Schroeder T.M., Bailey J., Gopalakrishnan R., Westendorf J.J. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J. Bone Miner. Res. 2008, 23:361-372.
33. Jensen E.D., Gopalakrishnan R., Westendorf J.J. Bone morphogenic protein 2 activates protein kinase D to regulate histone deacetylase 7 localization and repression of Runx2. J. Biol. Chem. 2009, 284:2225-2234.
34. Jeon E.J., et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J. Biol. Chem. 2006, 281:16502-16511.
35. Juan L.J., et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 2000, 275:20436-20443.
36. Kang J.S., Alliston T., Delston R., Derynck R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J. 2005, 24:2543-2555.
37. Kim S.H., Lee J.W., Choi K.G., Chung H.W., Lee H.W. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. 2007, 10:291-295.
38. Knutson S.K., Chyla B.J., Amann J.M., Bhaskara S., Huppert S.S., Hiebert S.W. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 2008, 27:1017-1028.
39. Kumagai T., et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 2007, 121:656-665.
40. Lagger G., et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002, 21:2672-2681.
41. Lahm A., et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl Acad. Sci. USA 2007, 104:17335-17340.
42. Lamour V., Detry C., Sanchez C., Henrotin Y., Castronovo V., Bellahcene A. Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J. Biol. Chem. 2007, 282:36240-36249.
43. Lee S.K., Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999, 140:3552-3561.
44. Lee H.W., Suh J.H., Kim A.Y., Lee Y.S., Park S.Y., Kim J.B. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol. Endocrinol. 2006, 20:2432-2443.
45. Lee S., et al. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif. 2009, 42:711-720.
46. Lehrman G., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
47. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 2008, 358:1304-1306.
48. Li H., et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J. Clin. Invest. 2009, 119:3666-3677.
49. Li Y., Backesjo C.M., Haldosen L.A., Lindgren U. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur. J. Pharmacol. 2009, 609:13-18.
50. Li Z., et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J. Biol. Chem. 2009, 284:15676-15684.
51. Lin H.S., et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 2007, 150:862-872.
52. Loscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem. Pharmacol. 1981, 30:1364-1366.
53. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
54. Martin R.B. Size, structure and gender: lessons about fracture risk. J. Musculoskelet. Neuronal Interact. 2002, 2:209-211.
55. McGee-Lawrence M.E., McCleary-Wheeler A.L., Zhang M., Stensgard B.A., Lian J.B., Westendorf J.J. Histone Deacetylase Inhibition Causes Bone Loss, ASBMR 32nd Annual Meeting 2010, American Society for Bone and Mineral Research, Toronto, ON, Canada, Plenary Poster #0207.
56. Montgomery R.L., et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007, 21:1790-1802.
57. Montgomery R.L., et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J. Clin. Invest. 2008, 118:3588-3597.
58. Nakamura T., et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J. Immunol. 2005, 175:5809-5816.
59. Nissen-Meyer L.S., et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007, 48:1850-1860.
60. Oner N., Kaya M., Karasalihoglu S., Karaca H., Celtik C., Tutunculer F. Bone mineral metabolism changes in epileptic children receiving valproic acid. J. Paediatr. Child Health 2004, 40:470-473.
61. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/Bmp signaling and the chemokine spingosine-1 phosphate. Proc Natl Acad Sci U S A 2008, 105:20674-20679.
62. Pettit A.R., Chang M.K., Hume D.A., Raggatt L.J. Osteal macrophages: a new twist on coupling during bone dynamics. Bone 2008, 43:976-982.
63. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 276:36734-36741.
64. Pratap J., Akech J., Wixted J.J., Szabo G., Hassain S., McGee-Lawrence M.E., Li X., Bedard K., Dhillon R.J., van Wijnen A.J., Stein J.L., Stein G.S., Westendorf J.J., Lian J.B. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Molecular Cancer Therapeutics 2010, 9:3210-3220.
65. Rahman M.M., Kukita A., Kukita T., Shobuike T., Nakamura T., Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003, 101:3451-3459.
66. Ramalingam S.S., et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 2007, 13:3605-3610.
67. Razidlo D.F., et al. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS ONE 2010, 5:e11492.
68. Rieger-Wettengl G., et al. Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics 2001, 108:E107.
69. Rivadeneira F., et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet. 2009, 41:1199-1206.
70. Robling A.G., Castillo A.B., Turner C.H. Biomechanical and molecular regulation of bone remodeling. Annu. Rev. Biomed. Eng. 2006, 8:455-498.
71. Ruggiero S.L., Drew S.J. Osteonecrosis of the jaws and bisphosphonate therapy. J. Dent. Res. 2007, 86:1013-1021.
72. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 2004, 62:527-534.
73. Sakata R., Minami S., Sowa Y., Yoshida M., Tamaki T. Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem. Biophys. Res. Commun. 2004, 315:959-963.
74. Sato Y., et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445-449.
75. Schneider J.P. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009, 64:18-23.
76. Schroeder T.M., Westendorf J.J. Histone deacetylase inhibitors promote osteoblast maturation. J. Bone Miner. Res. 2005, 20:2254-2263.
77. Schroeder T.M., Kahler R.A., Li X., Westendorf J.J. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J. Biol. Chem. 2004, 279:41998-42007.
78. Schroeder T.M., Jensen E.D., Westendorf J.J. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res. C Embryo Today 2005, 75:213-225.
79. Senn, S.M., Kantor, S., Poulton, I.J., Morris, M.J., Sims, N.A., O'Brien, T.J., Wark, J.D. 2010. Adverse effects of valproate on bone: defining a model to investigate the pathophysiology. Epilepsia 51, 984-993.
80. Sheth R.D., et al. Effect of carbamazepine and valproate on bone mineral density. J. Pediatr. 1995, 127:256-262.
81. Shimizu E., Selvamurugan N., Westendorf J.J., Partridge N.C. Parathyroid hormone regulates histone deacetylases in osteoblasts. Ann. NY Acad. Sci. 2007, 1116:349-353.
82. Shimizu E., Selvamurugan N., Westendorf J.J., Olson E.N., Partridge N.C. HDAC4 represses matrix metalloproteinase-13 transcription in osteoblastic cells, and parathyroid hormone controls this repression. J. Biol. Chem. 2010, 285:9616-9626.
83. Solomon D.H., Rekedal L., Cadarette S.M. Osteoporosis treatments and adverse events. Curr. Opin. Rheumatol. 2009, 21:363-368.
84. Subha K., Kumar G.R. Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis. Bioinformation 2008, 3:218-222.
85. Tang Y., et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 2009, 15:757-765.
86. Tsukahara H., et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr. Int. 2002, 44:247-253.
87. Vahle J.L., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2years and relevance to human safety. Toxicol. Pathol. 2002, 30:312-321.
88. Vahle J.L., Long G.G., Sandusky G., Westmore M., Ma Y.L., Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol. 2004, 32:426-438.
89. Vajda F.J., et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J. Clin. Neurosci. 2004, 11:854-858.
90. van der Laan J.W., de Boer T., Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J. Neurochem. 1979, 32:1769-1780.
91. Vega R.B., et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119:555-566.
92. Verdel A., Khochbin S. Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. J. Biol. Chem. 1999, 274:2440-2445.
93. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
94. Warrener R., et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 2003, 17:1550-1552.
95. Westendorf J.J., et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol. Cell. Biol. 2002, 22:7982-7992.
96. Wu M., et al. Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivo. Bone 2009, 44:528-536.
97. Yang X.J., Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr. Opin. Genet. Dev. 2003, 13:143-153.
98. Yi T., et al. Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp. Mol. Med. 2007, 39:213-221.
99. You L., et al. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone 2008, 42:172-179.
100. Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307:269-273.
101. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110:479-488.
102. Zhang Y., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 2008, 28:1688-1701.
103. Zimmermann S., et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 2007, 67:9047-9054.